C4 Therapeutics (CCCC) Earnings Date & Reports

Key Takeaways

• C4 Therapeutics reported a third-quarter 2026 net loss of $21.8 million, or $0.16 per share, narrowing from a $32.2 million loss, or $0.44 per share, in the same period a year earlier.
• The company's loss per share came in better than the Wall Street consensus of roughly a $0.20 per-share loss, while revenue of $8.5 million landed slightly below expectations.
• Revenue declined from $11.2 million in Q3 2025, mainly reflecting the conclusion of certain research activities tied to its Merck and Merck KGaA collaborations.
• Cash, cash equivalents, and marketable securities totaled $274.7 million as of September 30, 2026, which management expects to fund operations into the end of 2028.
• The lead program, cemsidomide, remains on track, with its Phase 2 MOMENTUM trial expected to complete enrollment in Q1 2027 and initial response data anticipated in the second half of 2027.
• For additional detail, explore the company's Major News, Today's Price Move, Price Targets, and Forecast pages.
• You can also discover timely trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

As a clinical-stage biopharmaceutical company, C4 Therapeutics generates most of its quarterly revenue from collaboration agreements rather than product sales, making its financial statements only part of the story. What investors watch most closely is the progress of cemsidomide, the company's investigational oral protein degrader for multiple myeloma, and the cash runway supporting its clinical programs. This Q3 2026 report matters because it pairs a shrinking net loss with a pipeline update, reinforcing whether the company can sustain development through major clinical milestones expected in 2027. With no approved products yet, disciplined spending and successful trial execution are the key signals behind the numbers.

Reported Results

C4 Therapeutics reported total revenue of $8.5 million for the third quarter of 2026, down from $11.2 million in the year-ago quarter. The decline was primarily driven by the conclusion of certain 2025 research activities under its collaborations with Merck and Merck KGaA, partially offset by higher revenue recognized under the Roche Degrader-Antibody Conjugate collaboration agreement. Revenue landed slightly below consensus estimates near $8.5 million.

Research and development (R&D) expense was $24.8 million, down from $26.0 million a year earlier, while general and administrative (G&A) expense declined to $8.3 million from $8.9 million, reflecting lower stock-based compensation costs. The company reported a net loss of $21.8 million, or $0.16 per share, narrowing from $32.2 million, or $0.44 per share, in Q3 2025. The per-share loss beat consensus expectations of roughly $0.20.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those following CCCC or similar names, the AI Screener can help streamline your research process.

Market Reaction and Investor Sentiment

Investor attention around C4 Therapeutics remains firmly anchored to cemsidomide's clinical trajectory rather than its quarterly revenue, which is inherently lumpy because it depends on collaboration milestones. The narrower loss and stable cash position were viewed favorably, while the modest revenue miss drew limited concern given the expected wind-down of earlier collaboration research activities. Sentiment continues to hinge on the pipeline: management confirmed the Phase 2 MOMENTUM trial is on track to complete enrollment in Q1 2027, with initial overall response rate (ORR) data expected in the second half of 2027. Near-term volatility is likely to track clinical updates and upcoming investor conferences more than headline financial figures.

Forward Outlook and Key Factors to Monitor

The company reiterated that its current cash position of $274.7 million is expected to fund its operating plan through the end of 2028, reducing near-term financing risk and giving management room to advance its programs without immediate dilution pressure.

Investors should monitor the Phase 1b trial evaluating cemsidomide in combination with elranatamab (ELREXFIO), a BCMA-targeted bispecific antibody. The trial has advanced to higher dose cohorts, and data from all evaluated cohorts is expected in mid-2027.

Looking further ahead, C4 Therapeutics plans to initiate an additional Phase 1b trial in the first half of 2027 testing cemsidomide alongside approved multiple myeloma therapies. The most significant catalyst remains the Phase 2 MOMENTUM trial, where initial investigator-assessed response data is expected in the second half of 2027. Spending trends, collaboration revenue recognition, and execution against these clinical timelines will shape the narrative over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations